RASAGILINE VIATRIS 1 mg, tablet 30 tablets, CIP 3400930059937
Active ingredients: Rasagiline, Rasagiline tartrate
Commercialized according to BDPMDispensing in France: Prescription only
Tablet30 tablets, CIP 3400930059937orale
No current ANSM shortage notice is included
Package details
Original BDPM fields are shown in French.
- Official name
- RASAGILINE VIATRIS 1 mg, comprimé
- Pharmaceutical form
- comprimé
- Route of administration
- orale
- Presentation description
- plaquette(s) OPA : polyyamide orienté aluminium PVC-Aluminium de 30 comprimé(s)
- Marketing authorisation holder
- VIATRIS (IRLANDE)
- Reimbursement according to BDPM
- 65 %
- Approval for use in healthcare institutions
- oui
- Commercialization declaration date
- 28 Apr 2025
- Prescription and dispensing conditions
- Prescription only
- List I: prescription-only medicine
- Enhanced ANSM monitoring
- No
BDPM identifiers
CIS
62240543CIP73005993CIP133400930059937Composition in BDPM
| Component | Amount per unit | Source type |
|---|---|---|
| RASAGILINEcomprimé | 1 mg · un comprimé | FT |
| TARTRATE DE RASAGILINEcomprimé | 1,44 mg · un comprimé | SA |
Information is based on BDPM data and is for reference only. Consult a doctor before use.
Other packages of this medicine
The same medicine in another pack size, according to BDPM.
Similar medicines
Similar medicines are listed using the official BDPM catalog. Availability must be checked separately. Consult a doctor or pharmacist before switching medicines.